Pioglitazone

• Description :

  Pioglitazone (U 72107) is an orally active and selective PPARγ (peroxisome proliferator-activated receptor) agonist with high affinity binding to the PPARγ ligand-binding domain with EC50 of 0.93 and 0.99 μM for human and mouse PPARγ, respectively. Pioglitazone can be used in diabetes research[2][3][4].

• Product Name Alternative :

  U 72107

• UNSPSC :

  12352005

• Hazard Statement :

  H302, H312, H332, H350, H360

• Target :

  Ferroptosis; PPAR

• Type :

  Reference compound

• Related Pathways :

  Apoptosis; Cell Cycle/DNA Damage; Metabolic Enzyme/Protease; Vitamin D Related/Nuclear Receptor

• Applications :

  Cancer-Kinase/protease

• Field of Research :

  Metabolic Disease; Cancer

• Assay Protocol :

  https://www.medchemexpress.com/pioglitazone.html

• Concentration :

  10mM

• Purity :

  99.89

• Solubility :

  DMSO : 25 mg/mL (ultrasonic; warming; heat to 60°C)

• Smiles :

  O=C(N1)SC(CC2=CC=C(OCCC3=NC=C(CC)C=C3)C=C2)C1=O

• Molecular Formula :

  C19H20N2O3S

• Molecular Weight :

  356.44

• Precautions :

  H302, H312, H332, H350, H360

• References & Citations :

  [1]Kuwabara K, et al. A novel selective peroxisome proliferator-activated receptor alpha agonist, 2-methyl-c-5-[4-[5-methyl-2- (4-methylphenyl) -4-oxazolyl]butyl]-1,3-dioxane-r-2-carboxylic acid (NS-220), potently decreases plasma triglyceride and glucose leve|[2]Puddu A, et al. Pioglitazone attenuates the detrimental effects of advanced glycation end-products in the pancreatic beta cell line HIT-T15. Regul Pept. 2012 Aug 20;177 (1-3) :79-84.|[3]Kubota N, et al. Pioglitazone ameliorates insulin resistance and diabetes by both adiponectin-dependent and -independent pathways. J Biol Chem. 2006 Mar 31;281 (13) :8748-55.|[4]Elrashidy RA, et al. Pioglitazone attenuates cardiac fibrosis and hypertrophy in a rat model of diabetic nephropathy. J Cardiovasc Pharmacol Ther. 2012 Sep;17 (3) :324-33.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  Launched

• Isoform :

  PPARα; PPARβ/δ; PPARγ

• Citation 01 :

  Acta Pharmacol Sin. 2021 Jan;42 (1) :160-170.|Adv Sci (Weinh) . 2024 Dec 25:e2407134.|Adv Sci (Weinh) . 2024 Nov;11 (44) :e2401931.|Adv Sci (Weinh) . 2025 Nov 11:e08957.|Am J Chin Med. 2025;53 (1) :251-283.|Am J Physiol Heart Circ Physiol. 2021 Jun 1;320 (6) :H2222-H2239.|Am J Physiol Renal Physiol. 2019 Jul 1;317 (1) :F137-F151.|Biochem Eng J. 2021, 108104.|Biochem Pharmacol. 2025 Oct:240:117120.|Biol Proced Online. 2025 Jun 16;27 (1) :21.|BMC Complement Med Ther. 2022 Jul 1;22 (1) :176.|Br J Pharmacol. 2021 Jun;178 (11) :2305-2323.|Cancer Res. 2022 Apr 15;82 (8) :1503-1517.|Cell Metab. 2021 Mar 2;33 (3) :581-597.e9.|Cell Stem Cell. 2022 Sep 1;29 (9) :1366-1381.e9.|Eur J Pharmacol. 2025 Sep 15:1003:177943.|Food Chem Toxicol. 2021 Jun:152:112183.|Gut Microbes. 2022 Jan-Dec;14 (1) :2139978.|Heliyon. 2023 Apr 1;9 (4) :e15146.|Immunology. 2023 Jul;169 (3) :271-291.|Immunopharmacol Immunotoxicol. 2021 Dec;43 (6) :704-712.|J Adv Res. 2025 Aug:74:429-442.|J Ethnopharmacol. 2024 Nov 29:340:119128.|J Steroid Biochem Mol Biol. 2023 May:229:106265.|Med Sci Monit. 2019 Nov 13;25:8544-8553.|Nat Commun. 2025 Sep 10;16 (1) :8215.|Nutr Metab. 2019 Mar 5:16:17.|Oxid Med Cell Longev. 2022 Dec 5:2022:2226168.|Res Sq. 2024 Jul 12.|Research Square Preprint. 2021 Mar.|Sci China Chem. 2025 Jun 30.|SSRN. 2023 May 30.|SSRN. 2025 Jul 8.|Tunku Abdul Rahman University. 2024 Mar 11.|Inflammation. 2020 Apr;43 (2) :568-578.|Int J Oncol. 2018 Aug;53 (2) :551-566.|J Diabetes Res. 2019 Feb 3:2019:5245063.|Mol Med Rep. 2024 Nov;30 (5) :209.|Mol Med Rep. 2019 Jan;19 (1) :400-406.

• CAS Number :

  [111025-46-8]